Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

All NewsJuly 1, 2025

Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent